The Immune Paradox of Sarcoidosis: A Review of Literature

References (145)

1. 1 A Case Control Etiologic Study of Sarcoidosis [DOI]
2. 2 Familial Aggregation of Sarcoidosis [DOI]
3. 3 Mycobacterial catalase–peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis [DOI]
4. 4 MicroRNA-29 Regulates T-Box Transcription Factors and Interferon-γ Production in Helper T Cells [DOI]
5. 5 Sarcoidosis [DOI]
6. 6 Racial difference in cardiac sarcoidosis incidence observed at autopsy.
7. 7 Lofgren's Syndrome: Human Leukocyte Antigen Strongly Influences the Disease Course [DOI]
8. 8 The BTNL2 Gene and Sarcoidosis Susceptibility in African Americans and Whites [DOI]
9. 9 The role of miRNA-29 family in cancer [DOI]
10. 10 The Immunology of Sarcoidosis [DOI]
11. 11 Review: Analysis of exhaled breath condensate in respiratory medicine: methodological aspects and potential clinical applications [DOI]
12. 12 Noninvasive methods for assessment of airway inflammation in occupational settings [DOI]
13. 13 MicroRNA-29 in the adaptive immune system: setting the threshold [DOI]
14. 14 Treatment of Sarcoidosis [DOI]
15. 15 IL-12 and IL-18 Are Increased and Stimulate IFN-γ Production in Sarcoid Lungs [DOI]
16. 16 HLA-DQB1*0201 [DOI]
17. 17 Role of IL-15, IL-2, and their receptors in the development of T cell alveolitis in pulmonary sarcoidosis [DOI]
18. 18 CD28 Function: A Balance of Costimulatory and Regulatory Signals [DOI]
19. 19 Job and Industry Classifications Associated With Sarcoidosis in a Case–Control Etiologic Study of Sarcoidosis (ACCESS) [DOI]
20. 20 Th1 cytokine pattern in sarcoidosis is expressed by bronchoalveolar CD4+ and CD8+ T cells [DOI]
21. 21 State of the Art. Role of CD4+ T Cells in Sarcoidosis [DOI]
22. 22 Identification of HLA-DR–bound peptides presented by human bronchoalveolar lavage cells in sarcoidosis [DOI]
23. 23 Propionibacterium acnes is the most common bacterium commensal in peripheral lung tissue and mediastinal lymph nodes from subjects without sarcoidosis.
24. 24 Toll-like receptor (TLR) 4 polymorphisms are associated with a chronic course of sarcoidosis [DOI]
25. 25 The Anergic State in Sarcoidosis Is Associated with Diminished Dendritic Cell Function [DOI]
26. 26 Etiology of sarcoidosis: does infection play a role?
27. 27 Expression of Th1 markers by lung accumulated T cells in pulmonary sarcoidosis [DOI]
28. 28 MultipleMycobacteriumantigens induce interferon-γ production from sarcoidosis peripheral blood mononuclear cells [DOI]
29. 29 Chitotriosidase and soluble IL‐2 receptor: Comparison of two markers of sarcoidosis severity [DOI]
30. 30 Autoimmune T cell responses to antigenic peptides presented by bronchoalveolar lavage cell HLA-DR molecules in sarcoidosis [DOI]
31. 31 Differential expression of microRNA and predicted targets in pulmonary sarcoidosis [DOI]
32. 32 Toll-like receptor (TLR)-9 genetics and function in sarcoidosis [DOI]
33. 33 Is mycobacterial heat shock protein 16kDa, a marker of the dormant stage of Mycobacterium tuberculosis, a sarcoid antigen? [DOI]
34. 34 The Major Histocompatibility Complex Gene Region and Sarcoidosis Susceptibility in African Americans [DOI]
35. 35 TH1/TH2 and TC1/TC2 profiles in peripheral blood and bronchoalveolar lavage fluid cells in pulmonary sarcoidosis [DOI]
36. 36 Protein Profiles of Bronchoalveolar Lavage Fluid from Patients with Pulmonary Sarcoidosis [DOI]
37. 37 Differentiation of sarcoidosis from tuberculosis using real-time PCR assay for the detection and quantification of Mycobacterium tuberculosis.
38. 38 Toll-like receptor (TLR) 4 polymorphism Asp299Gly is not associated with disease course in Dutch sarcoidosis patients [DOI]
39. 39 L’enzyme de conversion de l’angiotensine I (ECA) dans le diagnostic de la sarcoïdose [DOI]
40. 40 Inflammatory markers in the exhaled breath condensate of patients with pulmonary sarcoidosis.
41. 41 Treatment of Sarcoidosis [DOI]
42. 42 Analysis of T cell subsets and beta chemokines in patients with pulmonary sarcoidosis [DOI]
43. 43 Prolonged culture for mycobacteria in mediastinal lymph nodes from patients with pulmonary sarcoidosis. A negative study.
44. 44 Antibody to herpes-like virus in sarcoidosis. [DOI]
45. 45 [Peroxisome proliferator-activated receptors-gamma (PPAR-gamma) and their role in immunoregulation and inflammation control].
46. 46 Peripheral anergy and local immune hyperactivation in sarcoidosis: a paradox or birds of a feather [DOI]
47. 47 Intracellular detection of interleukin 17 and other cytokines in human bronchoalveolar lavage fluid: A first assessment [DOI]
48. 48 Severe calcification of the aorta (porcelain aorta) associated with sarcoidosis in a pediatric heart transplant recipient [DOI]
49. 49 Laboratory Investigations and Immunological Testing in Sarcoidosis [DOI]
50. 50 From Mycobacteria to Sarcoidosis – Is the Gate Still Open? [DOI]
51. 51 The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-γ [DOI]
52. 52 Sarcoidosis is associated with a truncating splice site mutation in BTNL2 [DOI]
53. 53 Genome-wide association study identifies ANXA11 as a new susceptibility locus for sarcoidosis [DOI]
54. 54 Serum Amyloid A Regulates Granulomatous Inflammation in Sarcoidosis through Toll-like Receptor-2 [DOI]
55. 55 Endosonography vs Conventional Bronchoscopy for the Diagnosis of Sarcoidosis [DOI]
56. 56 Results from a Genome-wide Search for Predisposing Genes in Sarcoidosis [DOI]
57. 57 Sarcoidosis—scientific progress and clinical challenges [DOI]
58. 58 T Cell Responses to Mycobacterial Catalase-Peroxidase Profile a Pathogenic Antigen in Systemic Sarcoidosis [DOI]
59. 59 Potential Usefulness of Inflammatory Markers to Monitor Respiratory Functional Impairment in Sarcoidosis [DOI]
60. 60 Phenotyping Sarcoidosis from a Pulmonary Perspective [DOI]
61. 61 Recent Advances in Sarcoidosis [DOI]
62. 62 A WORLDWIDE REVIEW OF SARCOIDOSIS* [DOI]
63. 63 Bronchoalveolar Lavage Cell Populations in the Diagnosis of Sarcoidosis [DOI]
64. 64 Sarcoidosis: clinical update [DOI]
65. 65 Cytokine profile and proteome analysis in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis [DOI]
66. 66 pSTAT1, pSTAT3, and T‐bet expression in peripheral blood mononuclear cells from relapsing‐remitting multiple sclerosis patients correlates with disease activity [DOI]
67. 67 Comparative Evaluation of Serum Markers in Pulmonary Sarcoidosis [DOI]
68. 68 Bronchoalveolar Lavage in Sarcoidosis [DOI]
69. 69 Genome-wide search for sarcoidosis susceptibility genes in African Americans [DOI]
70. 70 Peroxisome Proliferator–Activated Receptor γ Activity Is Deficient in Alveolar Macrophages in Pulmonary Sarcoidosis [DOI]
71. 71 Deficiency of a subset of T-cells with immunoregulatory properties in sarcoidosis [DOI]
72. 72 Phenotypic analysis of lymphocytes and monocytes/macrophages in peripheral blood and bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis [DOI]
73. 73 HLA‐DQB1*0601 is primarily associated with the susceptibility to cardiac sarcoidosis [DOI]
74. 74 Markers of Inflammation in Sarcoidosis: Blood, Urine, BAL, Sputum, and Exhaled Gas [DOI]
75. 75 Genetic variation in the Toll‐like receptor gene cluster (TLR10‐TLR1‐TLR6) influences disease course in sarcoidosis [DOI]
76. 76 Treatment of Sarcoidosis [DOI]
77. 77 Immunopathogenesis of sarcoidosis [DOI]
78. 78 Diagnostic role of BAL fluid CD4/CD8 ratio in different radiographic and clinical forms of pulmonary sarcoidosis [DOI]
79. 79 Sarcoidosis: histopathological definition and clinical diagnosis. [DOI]
80. 80 Th1/Th2 Cell Distribution in Pulmonary Sarcoidosis [DOI]
81. 81 Genetic Basis of Remitting Sarcoidosis [DOI]
82. 82 Increased circulating interleukin-12 (IL-12) p40 in pulmonary sarcoidosis [DOI]
83. 83 Induced sputum compared to bronchoalveolar lavage for evaluating patients with sarcoidosis and non-granulomatous interstitial lung disease [DOI]
84. 84 Potential biomarkers for diagnosis of sarcoidosis using proteomics in serum [DOI]
85. 85 High Prevalence of Mycobacterium tuberculosis DNA in Biopsies from Sarcoidosis Patients from Catalonia, Spain [DOI]
86. 86 From Hutchinson to now: a historical glimpse [DOI]
87. 87 Exhaled breath condensate: a new method for lung disease diagnosis [DOI]
88. 88 T-helper cell type-1 transcription factor T-bet is upregulated in pulmonary sarcoidosis [DOI]
89. 89 Measurement of neopterin, TGF-β1and ACE in the exhaled breath condensate of patients with sarcoidosis [DOI]
90. 90 The potential of the immunological markers of sarcoidosis in exhaled breath and peripheral blood as future diagnostic and monitoring techniques [DOI]
91. 91 Use of discriminant analysis in assessing pulmonary function worsening in patients with sarcoidosis by a panel of inflammatory biomarkers [DOI]
92. 92 Mycobacteria and sarcoidosis [DOI]
93. 93 Th1/Th2 cytokine pattern in bronchoalveolar lavage fluid and induced sputum in pulmonary sarcoidosis [DOI]
94. 94 Expression of Receptor for Advanced Glycation End Products in Sarcoid Granulomas [DOI]
95. 95 Granulomatous pneumonitis following bone marrow transplantation [DOI]
96. 96 Intracellular cytokine profiles and T cell activation in pulmonary sarcoidosis [DOI]
97. 97 Aetiology of Sarcoidosis [DOI]
98. 98 HLA-DQB1 and HLA-DPB1 genotypes in familial sarcoidosis [DOI]
99. 99 Involvement of Discoidin Domain Receptor 1 in the Deterioration of Pulmonary Sarcoidosis [DOI]
100. 100 Elevated Levels of Type II Soluble Tumor Necrosis Factor Receptors in the Bronchoalveolar Lavage Fluids of Patients with Sarcoidosis [DOI]
101. 101 miR-29 Is a Major Regulator of Genes Associated with Pulmonary Fibrosis [DOI]
102. 102 The immune paradox of sarcoidosis and regulatory T cells [DOI]
103. 103 Sarcoidosis is a Th1/Th17 multisystem disorder [DOI]
104. 104 ETIOLOGY OF SARCOIDOSIS [DOI]
105. 105 Cellular Recognition of Mycobacterium tuberculosis ESAT-6 and KatG Peptides in Systemic Sarcoidosis [DOI]
106. 106 Comparison of Biomarkers in Exhaled Breath Condensate and Bronchoalveolar Lavage [DOI]
107. 107 Etiology of Sarcoidosis [DOI]
108. 108 Evidence for Mycobacteria in Sarcoidosis [DOI]
109. 109 A Current Assessment of Rurally Linked Exposures as Potential Risk Factors for Sarcoidosis [DOI]
110. 110 Multiple mycobacterial antigens are targets of the adaptive immune response in pulmonary sarcoidosis [DOI]
111. 111 Role of MicroRNAs in Lung Disease [DOI]
112. 112 Gamma interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis. [DOI]
113. 113 HLA-DR Predicts the Prognosis in Scandinavian Patients with Pulmonary Sarcoidosis [DOI]
114. 114 Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis [DOI]
115. 115 New pathogenetic insights into the sarcoid granuloma [DOI]
116. 116 The CD4/CD8 ratio in BAL fluid is highly variable in sarcoidosis [DOI]
117. 117 Cells and cytokines involved in the pathogenesis of sarcoidosis.
118. 118 CD4/CD8 ratios in bronchoalveolar lavage fluid: of value for diagnosing sarcoidosis? [DOI]
119. 119 Human Leukocyte Antigen-DRB1 Position 11 Residues Are a Common Protective Marker for Sarcoidosis [DOI]
120. 120 Exosome-enclosed microRNAs in exhaled breath hold potential for biomarker discovery in patients with pulmonary diseases [DOI]
121. 121 Dendritic Cells in the Pathogenesis of Sarcoidosis [DOI]
122. 122 Highly Activated T-Cell Receptor AV2S3+ CD4+ Lung T-Cell Expansions in Pulmonary Sarcoidosis [DOI]
123. 123 8-Isoprostane, a Marker of Oxidative Stress, Is Increased in the Expired Breath Condensate of Patients With Pulmonary Sarcoidosis [DOI]
124. 124 Chitotriosidase activity in patients with interstitial lung diseases [DOI]
125. 125 Exhaled Breath Condensate: A Promising Source for Biomarkers of Lung Disease [DOI]
126. 126 Donor-acquired sarcoidosis.
127. 127 Eicosanoids in Exhaled Breath Condensate and BAL Fluid of Patients With Sarcoidosis [DOI]
128. 128 The cause of sarcoidosis: the Centurial enigma solved [DOI]
129. 129 Recurrent sarcoid granulomas in a transplanted lung derive from recipient immune cells: Fig. 1— [DOI]
130. 130 Quantitative analysis of propionibacterial DNA in bronchoalveolar lavage cells from patients with sarcoidosis.
131. 131 Correlation between Eicosanoids in Bronchoalveolar Lavage Fluid and in Exhaled Breath Condensate [DOI]
132. 132 Antifungal medication is efficient in the treatment of sarcoidosis [DOI]
133. 133 A Genome-Wide Linkage Analysis in 181 German Sarcoidosis Families Using Clustered Biallelic Markers [DOI]
134. 134 Depressed peroxisome proliferator-activated receptor gamma (PPargamma) is indicative of severe pulmonary sarcoidosis: possible involvement of interferon gamma (IFN-gamma).
135. 135 Exhaled 8-isoprostane as a prognostic marker in sarcoidosis. A short term follow-up [DOI]
136. 136 Oral Lesion as the first Clinical Presentation in Sarcoidosis: A Case Report [DOI]
137. 137 [Comparison of oxidative stress markers in exhaled breath condensate and in serum of patients with tuberculosis and sarcoidosis].
138. 138 Induced Sputum in Patients With Newly Diagnosed Sarcoidosis [DOI]
139. 139 Correlation of CD4:CD8 ratio and tumour necrosis factor (TNF)alpha levels in induced sputum with bronchoalveolar lavage fluid in pulmonary sarcoidosis [DOI]
140. 140 Aetiologies of sarcoidosis [DOI]
141. 141 Antibodies to Epstein-Barr Virus and Some other Herpesviruses in Patients with Sarcoidosis, Pulmonary Tuberculosis and Erythema Nodosum [DOI]
142. 142 Markers of Fibrosis and Inflammation in Exhaled Breath Condensate (EBC) and Bronchoalveolar Lavage Fluid (BALF) of Patients with Pulmonary Sarcoidosis: A Pilot Study [DOI]
143. 143 Mycobacteria and sarcoidosis [DOI]
144. 144 Sarcoidosis is a multisystem disorder with variable prognosis - informations for treating physicians [DOI]
145. 145 American Journal of Respiratory Cell and Molecular Biology [DOI]

Cited by 0

No indexed citations yet.

Related research

• COPD: Immunopathogenesis and Immunological Markers — shares topic coverage